Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting® 2025, in Washington, D.C., evaluating the effects of semaglutide 2.4 mg in people with metabolic dysfunction-associated steatohepatitis (MASH) and moderate- to-advanced liver scarring (fibrosis). Results from a post hoc analysis of the ESSENCE phase 3 trial showed semaglutide 2.4 mg was associated with reduction in liver injury (steatohepatitis) in adults with MASH even at low levels of weight loss. “These data suggest that the effects of semaglutide 2.4 mg ...